Hexameric Multivalent Antibody Assembly via Disulfide Cross-Linking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing bispecific and multivalent antibodies face challenges such as high manufacturing costs, low yields, instability in serum, heterogeneity, and impaired binding affinity, making it difficult to create stable, homogeneous, and effective multivalent structures for biomedical applications.
Innovation Solution
A hexameric stably tethered structure comprising an IgG antibody and four antibody fragments, where AD2 moieties are covalently attached to DDD2 moieties via disulfide bonds, forming a stable complex that retains full functional properties and can be used for various therapeutic and diagnostic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If chemical cross-linking methods are used to produce multivalent antibodies, then binding affinity and avidity are improved, but manufacturing cost increases and product heterogeneity occurs
Solution Approach 1:
The patent introduces a dimerization domain as an intermediary component that mediates the assembly of antibody fragments into multivalent structures. This domain acts as a standardized interface that enables controlled dimerization without requiring chemical cross-linking, thereby reducing manufacturing complexity and cost while maintaining high binding affinity through proper spatial arrangement of antigen-binding sites.
Solution Approach 2:
The patent segments the antibody structure into separate functional domains: antigen-binding Fab regions and a dimerization domain. This segmentation allows independent optimization of binding affinity in the Fab regions while the dimerization domain controls the overall multivalent architecture, enabling modular assembly that reduces heterogeneity and simplifies manufacturing compared to chemical cross-linking approaches.
2Ease of manufacture
If recombinant engineering methods are used to produce bispecific antibodies, then manufacturing cost is reduced, but expression yields are low and stability in serum is poor
Solution Approach 1:
The patent changes key structural parameters by incorporating a dimerization domain that enforces a specific quaternary structure on the antibody assembly. This structural parameter change improves stability in serum by preventing dissociation of subunits and reduces aggregation, while the modular design maintains compatibility with recombinant expression systems, preserving cost advantages.
3Adaptability or versatility
If multiple product forms are present in the final product, then adaptability to different applications is improved, but manufacturing precision decreases due to undefined batch composition
Solution Approach 1:
The patent creates a universal multivalent antibody platform where the core dimerization domain serves multiple functions: it enables controlled assembly, ensures stability, and provides a standardized interface for attaching different antigen-binding specificities. This universal design allows production of various bispecific and multispecific antibodies with defined composition, maintaining manufacturing precision while achieving adaptability through modular exchange of antibody fragments.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The hexameric structure achieves higher binding affinity and increased efficacy compared to parent antibodies, with improved stability and homogeneity, enabling effective in vivo applications and overcoming the limitations of existing antibody production methods.
Implementation Method 1
AD2 moieties bound to the DDD2 moieties... where AD2 moieties are covalently attached to DDD2 moieties via disulfide bonds
Data Source
Figure 1
Figure 2
Figure 3A~3B
AI summary
The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Preferred embodiments concern hexameric stably tethered structures comprising one or more IgG antibody fragments and which may be monospecific or bispecific. The disclosed methods and compositions provide a facile and general way to obtain stably tethered structures of virtually any functionality and/or binding specificity. The stably tethered structures may be administered to subjects for diagnostic and/or therapeutic use, for example for treatment of cancer or autoimmune disease. The stably tethered structures may bind to and/or be conjugated to a variety of known effectors, such as drugs, enzymes, radionuclides, therapeutic agents and/or diagnostic agents.